Abnormal thiamine-dependent processes in Alzheimer's Disease. Lessons from diabetes

Molecular and Cellular Neuroscience

Volumn 55, Issue , 2013, Pages 17-25

  Gibson, Gary E ^a   Hirsch, Joseph A ^a   Cirio, Rosanna T ^a   Jordan, Barry D ^a   Fonzetti, Pasquale ^a   Elder, Jessica ^a  

^a BURKE MEDICAL RESEARCH INSTITUTE   (United States)

Author keywords

Alzheimer's disease; Diabetes; Mitochondria; Pentose shunt; Thiamine; Transketolase

Indexed keywords

ADVANCED GLYCATION END PRODUCT; BENFOTIAMINE; GLUCOSE; TAU PROTEIN; THIAMINE;

ALZHEIMER DISEASE; ARTICLE; COGNITIVE DEFECT; DISEASE COURSE; GLUCOSE METABOLISM; MEMORY DISORDER; NONHUMAN; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION;

ALZHEIMER DISEASE; ANIMALS; BRAIN; GLUCOSE; GLUCOSE METABOLISM DISORDERS; HUMANS; THIAMINE;

ANIMALIA;

EID: 84875656118     PISSN: 10447431     EISSN: 10959327     Source Type: Journal    
DOI: 10.1016/j.mcn.2012.09.001     Document Type: Article

References (102)

1. Ahmed N., Ahmed U., Thornalley P.J., Hager K., Fleischer G., Munch G. Protein glycation, oxidation and nitration adduct residues and free adducts of cerebrospinal fluid in Alzheimer's disease and link to cognitive impairment. J. Neurochem. 2005, 92:255-263.
2. Arvanitakis Z., Wilson R.S., Bienias J.L., Evans D.A., Bennett D.A. Diabetes mellitus and risk of Alzheimer disease and decline in cognitive function. Arch. Neurol. 2004, 61:661-666.
3. Atamna H., Kumar R. Protective role of methylene blue in alzheimer's disease via mitochondria and cytochrome c oxidase. J. Alzheimer's Dis. 2010, 20:S439-S452.
4. http://benfotiamine.org.
5. Bettendorff L. Thiamine. Present Knowledge in Nutrition 2012, Wiley-Blackwell. J.W. Erdman, I.A. MacDonald, S.H. Zeisel (Eds.).
6. Bettendorff L., Weekers L., Wins P., Schoffeniels E. Injection of sulbutiamine induces an increase in thiamine triphosphate in rat tissues. Biochem. Pharmacol. 1990, 40:2557-2560.
7. Bierhaus A., Hofmann M.A., Ziegler R., Nawroth P.P. AGEs and their interaction with AGE-receptors in vascular disease and diabetes mellitus. I. The AGE concept. Cardiovasc. Res. 1998, 37:586-600.
8. Bizot J.-C., Herpin A., Pothion S., Pirot S., Trovero F., Ollat H. Chronic treatment with sulbutiamine improves memory in an object recognition task and reduces some amnesic effects of dizocilpine in a spatial delayed-non-match-to-sample task. Prog. Neuropsychopharmacol. Biol. Psychiatry 2005, 29:928-935.
9. Blass J.P., Gleason P., Brush D., DiPonte P., Thaler H. Thiamine and Alzheimer's disease. A pilot study. Arch. Neurol. 1988, 45:833-835.
10. Bolanos J.P., Almeida A. The pentose-phosphate pathway in neuronal survival against nitrosative stress. IUBMB Life 2010, 62:14-18.
11. Bolanos J.P., Almeida A., Moncada S. Glycolysis: a bioenergetic or a survival pathway?. Trends Biochem. Sci. 2010, 35:145-149.
12. Brownlee M. Biochemistry and molecular cell biology of diabetic complications. Nature 2001, 414:813-820.
13. Brownlee M., Vlassara H., Kooney A., Ulrich P., Cerami A. Aminoguanidine prevents diabetes-induced arterial wall protein cross-linking. Science 1986, 232:1629-1632.
14. Bubber P., Haroutunian V., Fisch G., Blass J.P., Gibson G.E. Mitochondrial abnormalities in Alzheimer brain: mechanistic implications. Ann. Neurol. 2005, 57:695-703.
15. Burchell V.S., Gandhi S., Deas E., Wood N.W., Abramov A.Y., Plun-Favreau H. Targeting mitochondrial dysfunction in neurodegenerative disease: Part II. Expert Opin. Ther. Targets 2010, 14:497-511.
16. Butterworth R.F., Besnard A.M. Thiamine-dependent enzyme changes in temporal cortex of patients with Alzheimer's disease. Metab. Brain Dis. 1990, 5:179-184.
17. Calingasan N.Y., Uchida K., Gibson G.E. Protein-bound acrolein. J. Neurochem. 1999, 72:751-756.
18. Calingasan N.Y., Ho D.J., Wille E.J., Campagna M.V., Ruan J., Dumont M., Yang L., Shi Q., Gibson G.E., Beal M.F. Influence of mitochondrial enzyme deficiency on adult neurogenesis in mouse models of neurodegenerative diseases. Neuroscience 2008, 153:986-996.
19. Citron M. Alzheimer's disease: strategies for disease modification. Nat. Rev. Drug Discov. 2010, 9:387-398.
20. Craft S., Baker L.D., Montine T.J., Minoshima S., Watson G.S., Claxton A., Arbuckle M., Callaghan M., Tsai E., Plymate S.R., Green P.S., Leverenz J., Cross D., Gerton B. Intranasal insulin therapy for Alzheimer disease and amnestic mild cognitive impairment: a pilot clinical trial. Arch. Neurol. 2012, 69:29-38.
21. Demars M., Hu Y.-S., Gadadhar A., Lazarov O. Impaired neurogenesis is an early event in the etiology of familial Alzheimer's disease in transgenic mice. J. Neurosci. Res. 2010, 9999. NA.
22. Depeint F., Shangari N., Furrer R., Bruce W.R., O'Brien P.J. Marginal thiamine deficiency increases oxidative markers in the plasma and selected tissues in F344 rats. Nutr. Res. 2007, 27:698-704.
23. Du X.L., Edelstein D., Dimmeler S., Ju Q., Sui C., Brownlee M. Hyperglycemia inhibits endothelial nitric oxide synthase activity by posttranslational modification at the Akt site. J. Clin. Invest. 2001, 108:1341-1348.
24. Dumont M., Beal M.F. Neuroprotective strategies involving ROS in Alzheimer disease. Free Radic. Biol. Med. 2011, 51:1014-1026.
25. Dumont M., Lin M.T., Beal M.F. Mitochondria and antioxidant targeted therapeutic strategies for Alzheimer's disease. J. Alzheimers Dis. 2010, 20:633-643.
26. Eckert A., Schmitt K., Götz J. Mitochondrial dysfunction - the beginning of the end in Alzheimer's disease? Separate and synergistic modes of tau and amyloid-β toxicity. Alzheimer Res. Ther. 2011, 3:1-11.
27. Frank T., Bitsch R., Maiwald J., Stein G. High thiamine diphosphate concentrations in erythrocytes can be achieved in dialysis patients by oral administration of benfotiamine. Eur. J. Clin. Pharmacol. 2000, 56:251-257.
28. Gibson G.E., Blass J.P. Inhibition of acetylcholine synthesis and of carbohydrate utilization by maple-syrup-urine disease metabolites. J. Neurochem. 1976, 26:1073-1078.
29. Gibson G.E., Peterson C. Calcium and the aging nervous system. Neurobiol. Aging 1987, 8:329-343.
30. Gibson G.E., Jope R., Blass J.P. Decreased synthesis of acetylcholine accompanying impaired oxidation of pyruvic acid in rat brain minces. Biochem. J. 1975, 148:17-23.
31. Gibson G., Barclay L., Blass J. The role of the cholinergic system in thiamin deficiency. Ann. N. Y. Acad. Sci. 1982, 378:382-403.
32. Gibson G.E., Ksiezak-Reding H., Sheu K.-F.R., Mykytyn V., Blass J.P. Correlation of enzymatic, metabolic, and behavioral deficits in thiamin deficiency and its reversal. Neurochem. Res. 1984, 9:803-814.
33. Gibson G.E., Sheu K.-F.R., Blass J.P., Baker A., Carlson K.C., Harding B., Perrino P. Reduced activities of thiamine-dependent enzymes in the brains and peripheral tissues of patients with Alzheimer's disease. Arch. Neurol. 1988, 45:836-840.
34. Gibson G.E., Zhang H., Sheu K.F.R., Bogdanovich N., Lindsay J.G., Lannfelt L., Vestling M., Cowburn R.F. α-ketoglutarate dehydrogenase in Alzheimer brains bearing the APP670/671 mutation. Ann. Neurol. 1998, 44:676-681.
35. Gibson G.E., Park L.C.H., Zhang H.U.I., Sorbi S., Calingasan N.Y. Oxidative stress and a key metabolic enzyme in Alzheimer brains, cultured cells, and an animal model of chronic oxidative deficits. Ann. N. Y. Acad. Sci. 1999, 893:79-94.
36. Gibson G.E., Haroutunian V., Zhang H., Park L.C., Shi Q., Lesser M., Mohs R.C., Sheu R.K., Blass J.P. Mitochondrial damage in Alzheimer's disease varies with apolipoprotein E genotype. Ann. Neurol. 2000, 48:297-303.
37. Gibson G.E., Chen H.L., Xu H., Qiu L., Xu Z., Denton T.T., Shi Q. Deficits in the mitochondrial enzyme alpha-ketoglutarate dehydrogenase lead to Alzheimer's disease-like calcium dysregulation 2011, Neurobiol Aging.
38. Gold M., Hauser R.A., Chen M.F. Plasma thiamine deficiency associated with Alzheimer's disease but not Parkinson's disease. Metab. Brain Dis. 1998, 13:43-53.
39. Hakim A.M., Pappius H.M. Sequence of metabolic, clinical, and histological events in experimental thiamine deficiency. Ann. Neurol. 1983, 13:365-375.
40. Hammes H.P., Du X., Edelstein D., Taguchi T., Matsumura T., Ju Q., Lin J., Bierhaus A., Nawroth P., Hannak D., Neumaier M., Bergfeld R., Giardino I., Brownlee M. Benfotiamine blocks three major pathways of hyperglycemic damage and prevents experimental diabetic retinopathy. Nat. Med. 2003, 9:294-299.
41. Hata T., Stirling Meyer J., Tanahashi N., Ishikawa Y., Imai A., Shinohara T., Velez M., Fann W.E., Kandula P., Sakai F. Three-dimensional mapping of local cerebral perfusion in alcoholic encephalopathy with and without Wernicke-Korsakoff syndrome. J. Cereb. Blood Flow Metab. 1987, 7:35-44.
42. Hazell A.S., Butterworth R.F., Hakim A.M. Cerebral vulnerability is associated with selective increase in extracellular glutamate concentration in experimental thiamine deficiency. J. Neurochem. 1993, 61:1155-1158.
43. Herrero-Mendez A., Almeida A., Fernandez E., Maestre C., Moncada S., Bolanos J.P. The bioenergetic and antioxidant status of neurons is controlled by continuous degradation of a key glycolytic enzyme by APC/C-Cdh1. Nat. Cell Biol. 2009, 11:747-752.
44. Ito E., Oka K., Etcheberrigaray R., Nelson T.J., McPhie D.L., Tofel-Grehl B., Gibson G.E., Alkon D.L. Internal Ca2+ mobilization is altered in fibroblasts from patients with Alzheimer disease. Proc. Natl. Acad. Sci. U. S. A. 1994, 91:534-538.
45. Jack C.R., Knopman D.S., Jagust W.J., Shaw L.M., Aisen P.S., Weiner M.W., Petersen R.C., Trojanowski J.Q. Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade. Lancet Neurol. 2010, 9:119-128.
46. Jono T., Kimura T., Takamatsu J., Nagai R., Miyazaki K., Yuzuriha T., Kitamura T., Horiuchi S. Accumulation of imidazolone, pentosidine and N(epsilon)-(carboxymethyl)lysine in hippocampal CA4 pyramidal neurons of aged human brain. Pathol. Int. 2002, 52:563-571.
47. Karuppagounder S.S., Xu H., Shi Q., Chen L.H., Pedrini S., Pechman D., Baker H., Beal M.F., Gandy S.E., Gibson G.E. Thiamine deficiency induces oxidative stress and exacerbates the plaque pathology in Alzheimer's mouse model. Neurobiol. Aging 2009, 30:1587-1600.
48. Kauffman F.C. The quantitative histochemistry of enzymes of the pentose phosphate pathway in the central nervous system of the rat. J. Neurochem. 1972, 19:1-9.
49. Ke Z.J., Gibson G.E. Selective response of various brain cell types during neurodegeneration induced by mild impairment of oxidative metabolism. Neurochem. Int. 2004, 45:361-369.
50. Kopelman M.D. Frontal dysfunction and memory deficits in the alcoholic Korsakoff syndrome and Alzheimer-type dementia. Brain 1991, 114A:117-137.
51. Krautwald M., Munch G. Advanced glycation end products as biomarkers and gerontotoxins - A basis to explore methylglyoxal-lowering agents for Alzheimer's disease?. Exp. Gerontol. 2010, 45:744-751.
52. La Selva M., Beltramo E., Pagnozzi F., Bena E., Molinatti P.A., Molinatti G.M., Porta M. Thiamine corrects delayed replication and decreases production of lactate and advanced glycation end-products in bovine retinal and human umbilical vein endothelial cells cultured under high glucose conditions. Diabetologia 1996, 39:1263-1268.
53. Langbaum J.B.S., Chen K., Lee W., Reschke C., Bandy D., Fleisher A.S., Alexander G.E., Foster N.L., Weiner M.W., Koeppe R.A., Jagust W.J., Reiman E.M. Categorical and correlational analyses of baseline fluorodeoxyglucose positron emission tomography images from the Alzheimer's Disease Neuroimaging Initiative (ADNI). Neuroimage 2009, 45:1107-1116.
54. Leissring M.A., Akbari Y., Fanger C.M., Cahalan M.D., Mattson M.P., LaFerla F.M. Capacitative calcium entry deficits and elevated luminal calcium content in mutant presenilin-1 knockin mice. J. Cell Biol. 2000, 149:793-798.
55. Liu F., Iqbal K., Grundke-Iqbal I., Hart G.W., Gong C.-X. O-GlcNAcylation regulates phosphorylation of tau: A mechanism involved in Alzheimer's disease. Proc. Natl. Acad. Sci. U. S. A. 2004, 101:10804-10809.
56. Loew D. Pharmacokinetics of thiamine derivatives especially of benfotiamine. Int. J. Clin. Pharmacol. Ther. 1996, 34:47-50.
57. Lonsdale D. A review of the biochemistry, metabolism and clinical benefits of thiamin(e) and its derivatives. eCAM 2006, 3:49-59.
58. Loske C., Neumann A., Cunningham A.M., Nichol K., Schinzel R., Riederer P., Munch G. Cytotoxicity of advanced glycation endproducts is mediated by oxidative stress. J. Neural Transm. 1998, 105:1005-1015.
59. Loske C., Gerdemann A., Schepl W., Wycislo M., Schinzel R., Palm D., Riederer P., Munch G. Transition metal-mediated glycoxidation accelerates cross-linking of beta-amyloid peptide. Eur. J. Biochem. 2000, 267:4171-4178.
60. Manczak M., Mao P., Calkins M.J., Cornea A., Reddy A.P., Murphy M.P., Szeto H.H., Park B., Reddy P.H. Mitochondria-targeted antioxidants protect against amyloid-β toxicity in Alzheimer's Disease neurons. J. Alzheimers Dis. 2010, 20:609-631.
61. Meador K., Loring D., Nichols M., Zamrini E., Rivner M., Posas H., Thompson E., Moore E. Preliminary findings of high-dose thiamine in dementia of Alzheimer's type. J. Geriatr. Psychiatry Neurol. 1993, 6:222-229.
62. Meyer J.S., Tanahashi N., Ishikawa Y., Hata T., Velez M., Farm W.E., Kandula P., Mortel K.F., Rogers R.L. Cerebral atrophy and hypoperfusion improve during treatment of Wernicke-Korsakoff syndrome. J. Cereb. Blood Flow Metab. 1985, 5:376-385.
63. Micheau J., Durkin T.P., Destrade C., Rolland Y., Jaffard R. Chronic administration of sulbutiamine improves long term memory formation in mice: Possible cholinergic mediation. Pharmacol. Biochem. Behav. 1985, 23:195-198.
64. Mimori Y., Katsuoka H., Nakamura S. Thiamine therapy in Alzheimer's disease. Metab. Brain Dis. 1996, 11:89-94.
65. Morris J.C. The clinical dementia rating (CDR): current version and scoring rules. Neurology 1993, 43:2412-2414.
66. Munch G., Shepherd C.E., McCann H., Brooks W.S., Kwok J.B., Arendt T., Hallupp M., Schofield P.R., Martins R.N., Halliday G.M. Intraneuronal advanced glycation endproducts in presenilin-1 Alzheimer's disease. Neuroreport 2002, 13:601-604.
67. Netzel M., Ziems M., Jung K.H., Noll E., Borsch C., Bitsch I. Effect of high-dosed thiamine hydrochloride and S-benzoyl-thiamine-O-monophosphate on thiamine-status after chronic ethanol administration. Biofactors 2000, 11:111-113.
68. Nolan K.A., Black R.S., Sheu K.F., Langberg J., Blass J.P. A trial of thiamine in Alzheimer's disease. Arch. Neurol. 1991, 48:81-83.
69. Novello F., McLean P. The pentose phosphate pathway of glucose metabolism. Measurement of the non-oxidative reactions of the cycle. Biochem. J. 1968, 107:775-791.
70. Ollat H., Laurent B., Bakchine S., Michel B.F., Touchon J., B.D. Effects of the association of sulbutiamine with an acetylcholinesterase inhibitor in early stage and moderate Alzheimer disease. Encéphale 2007, 33:211-215.
71. Pan X., Gong N., Zhao J., Yu Z., Gu F., Chen J., Sun X., Zhao L., Yu M., Xu Z., Dong W., Qin Y., Fei G., Zhong C., Xu T.-L. Powerful beneficial effects of benfotiamine on cognitive impairment and {beta}-amyloid deposition in amyloid precursor protein/presenilin-1 transgenic mice. Brain 2010, 133:1342-1351.
72. Pan X., Gong N., Zhao J., Yu Z., Gu F., Chen J., Sun X., Zhao L., Yu M., Xu Z., Dong W., Qin Y., Fei G., Zhong C., Xu T.L. Powerful beneficial effects of benfotiamine on cognitive impairment and beta-amyloid deposition in amyloid precursor protein/presenilin-1 transgenic mice. Brain 2010, 133:1342-1351.
73. Park L.C.H., Zhang H., Sheu K.-F.R., Calingasan N.Y., Kristal B.S., Gordon Lindsay J., Gibson G.E. Metabolic Impairment induces oxidative stress, compromises inflammatory responses, and inactivates a key mitochondrial enzyme in microglia. J. Neurochem. 1999, 72:1948-1958.
74. Park L.C., Calingasan N.Y., Uchida K., Zhang H., Gibson G.E. Metabolic impairment elicits brain cell type-selective changes in oxidative stress and cell death in culture. J. Neurochem. 2000, 74:114-124.
75. Pekovich S.R., Martin P.R., Singleton C.K. Thiamine deficiency decreases steady-state transketolase and pyruvate dehydrogenase but not alpha-ketoglutarate dehydrogenase mRNA Levels in three human cell types. J. Nutr. 1998, 128:683-687.
76. Praticò D., Uryu K., Leight S., Trojanoswki J.Q., Lee V.M.-Y. Increased lipid peroxidation precedes amyloid plaque formation in an animal model of Alzheimer amyloidosis. J. Neurosci. 2001, 21:4183-4187.
77. Rafii M., Aisen P. Recent developments in Alzheimer's disease therapeutics. BMC Med. 2009, 7:7.
78. Reggiani C., Patrini C., Rindi G. Nervous tissue thiamine metabolism in vivo. I. Transport of thiamine and thiamine monophosphate from plasma to different brain regions of the rat. Brain Res. 1984, 293:319-327.
79. Reiman E.M., Chen K., Alexander G.E., Caselli R.J., Bandy D., Osborne D., Saunders A.M., Hardy J. Functional brain abnormalities in young adults at genetic risk for late-onset Alzheimer's dementia. Proc. Natl. Acad. Sci. U. S. A. 2004, 101:284-289.
80. Reisberg B., Doody R., Stöffler A., Schmitt F., Ferris S., Möbius H.J. Memantine in moderate-to-severe Alzheimer's disease. N. Engl. J. Med. 2003, 348:1333-1341.
81. Rodriguez J.J., Jones V.C., Tabuchi M., Allan S.M., Knight E.M., LaFerla F.M., Oddo S., Verkhratsky A. Impaired adult neurogenesis in the dentate gyrus of a triple transgenic mouse model of Alzheimer's disease. PLoS One 2008, 3:e2935.
82. Schenk G., Duggleby R.G., Nixon P.F. Properties and functions of the thiamin diphosphate dependent enzyme transketolase. Int. J. Biochem. Cell Biol. 1998, 30:1297-1318.
83. Shangari N., Bruce W.R., Poon R., O'Brien P.J. Toxicity of glyoxals-role of oxidative stress, metabolic detoxification and thiamine deficiency. Biochem. Soc. Trans. 2003, 31:1390-1393.
84. Shangari N., Depeint F., Furrer R., Bruce W.R., O'Brien P.J. The effects of partial thiamin deficiency and oxidative stress (i.e., glyoxal and methylglyoxal) on the levels of [alpha]-oxoaldehyde plasma protein adducts in Fischer 344 rats. FEBS Lett. 2005, 579:5596-5602.
85. Shi Q., Gibson G.E. Up-regulation of the mitochondrial malate dehydrogenase by oxidative stress is mediated by miR-743a. J. Neurochem. 2011, 118:440-448.
86. Sourris K.C., Harcourt B.E., Forbes J.M. A new perspective on therapeutic inhibition of advanced glycation in diabetic microvascular complications: common downstream endpoints achieved through disparate therapeutic approaches?. Am. J. Nephrol. 2009, 30:323-335.
87. Starkov A.A., Fiskum G., Chinopoulos C., Lorenzo B.J., Browne S.E., Patel M.S., Beal M.F. Mitochondrial alpha-ketoglutarate dehydrogenase complex generates reactive oxygen species. J. Neurosci. 2004, 24:7779-7788.
88. Stracke H., Hammes H.P., Werkmann D., Mavrakis K., Bitsch I., Netzel M., Geyer J., Kopcke W., Sauerland C., Bretzel R.G., Federlin K.F. Efficacy of benfotiamine versus thiamine on function and glycation products of peripheral nerves in diabetic rats. Exp. Clin. Endocrinol. Diabetes 2001, 109:330-336.
89. Stracke H., Gaus W., Achenbach U., Federlin K., Bretzel R.G. Benfotiamine in diabetic polyneuropathy (BENDIP): results of a randomised, double blind, placebo-controlled clinical study. Exp. Clin. Endocrinol. Diabetes 2008, 116:600,605.
90. Sudarsan N., Cohen-Chalamish S., Nakamura S., Emilsson G.M., Breaker R.R. Thiamine pyrophosphate riboswitches are targets for the antimicrobial compound pyrithiamine. Chem. Biol. 2005, 12:1325-1335.
91. Thornalley P.J., Jahan I., Ng R. Suppression of the accumulation of triosephosphates and increased formation of methylglyoxal in human red blood cells during hyperglycaemia by thiamine in vitro. J. Biochem. 2001, 129:543-549.
92. Thorpe S.R., Baynes J.W. Role of the Maillard reaction in diabetes mellitus and diseases of aging. Drugs Aging 1996, 9:69-77.
93. Torres L.L., Quaglio N.B., de Souza G.T., Garcia R.T., Dati L.M.M., Moreira W.L., de Melo Loureiro A.P., de souza-Talarico J.N., Smid J., Porto C.S., de Campos Bottino C.M., Nitrini R., de Moraes Barros S.B., Camarini R., Marcourakis T. Peripheral oxidative stress biomarkers in mild cognitive impairment and Alzheimer's disease. J. Alzheimers Dis. 2011, 26:59-68.
94. Tretter L., Adam-Vizi V. Generation of reactive oxygen species in the reaction catalyzed by alpha-ketoglutarate dehydrogenase. J. Neurosci. 2004, 24:7771-7778.
95. Voloboueva L.A., Lee S.W., Emery J.F., Palmer T.D., Giffard R.G. Mitochondrial protection attenuates inflammation-induced impairment of neurogenesis in vitro and in vivo. J. Neurosci. 2010, 30:12242-12251.
96. Volvert M.-L., Seyen S., Piette M., Evrard B., Gangolf M., Plumier J.-C., Bettendorff L. Benfotiamine, a synthetic S-acyl thiamine derivative, has different mechanisms of action and a different pharmacological profile than lipid-soluble thiamine disulfide derivatives. BMC Pharmacol. 2008, 8:10.
97. Wang Z., Pandey A., Hart G.W. Dynamic interplay between o-linked n-acetylglucosaminylation and glycogen synthase kinase-3-dependent phosphorylation. Mol. Cell. Proteomics 2007, 6:1365-1379.
98. Witt E.D., Goldman-Rakic P.S. Intermittent thiamine deficiency in the rhesus monkey. II. Evidence for memory loss. Ann. Neurol. 1983, 13:396-401.
99. Wong C.Y., Qiuwaxi J., Chen H., Li S.W., Chan H.T., Tam S., Shu X.O., Lau C.P., Kwong Y.L., Tse H.F. Daily intake of thiamine correlates with the circulating level of endothelial progenitor cells and the endothelial function in patients with type II diabetes. Mol. Nutr. Food Res. 2008, 52:1421-1427.
100. Zhang Q., Yang G., Li W., Fan Z., Sun A., Luo J., Ke Z.-J. Thiamine deficiency increases [beta]-secretase activity and accumulation of [beta]-amyloid peptides. Neurobiol. Aging 2011, 32:42-53.
101. Zhao J., Sun X., Yu Z., Pan X., Gu F., Chen J., Dong W., Zhao L., Zhong C. Exposure to pyrithiamine increases β-amyloid accumulation, Tau hyperphosphorylation, and glycogen synthase kinase-3 activity in the brain. Neurotox. Res. 2011, 19:575-583.
102. Ziems M., Netzel M., Bitsch I. Biokinetic parameters and metabolism of S-benzoylthiamine-O-monophosphate. Biofactors 2000, 11:109-110.